Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5509-5514.
Prepublished online as a Blood First Edition Paper on April 29, 2008; DOI 10.1182/blood-2008-02-136374.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figure
Right arrow All Versions of this Article:
blood-2008-02-136374v1
111/12/5509    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malumbres, R.
Right arrow Articles by Lossos, I. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malumbres, R.
Right arrow Articles by Lossos, I. S.
Related Collections
Right arrow Neoplasia
Right arrow Gene Expression
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP

Raquel Malumbres1, Jun Chen1, Rob Tibshirani2, Nathalie A. Johnson3, Laurie H. Sehn4, Yaso Natkunam5, Javier Briones6, Ranjana Advani7, Joseph M. Connors4, Gerald E. Byrne8, Ronald Levy7, Randy D. Gascoyne3,*, and Izidore S. Lossos1,*

1 Department of Medicine, Division of Hematology-Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, FL; 2 Department of Health Research and Policy, and Statistics, Stanford University, CA; 3 Department of Pathology, 4 Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC; 5 Department of Pathology, Stanford University School of Medicine, CA; 6 Department of Clinical Hematology, Hospital Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; 7 Department of Medicine, Division of Oncology, Stanford University School of Medicine, CA; and 8 Department of Pathology, University of Miami, FL

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by variable clinical outcomes. Outcome prediction at the time of diagnosis is of paramount importance. Previously, we constructed a 6-gene model for outcome prediction of DLBCL patients treated with anthracycline-based chemotherapies. However, the standard therapy has evolved into rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Herein, we evaluated the predictive power of a paraffin-based 6-gene model in R-CHOP–treated DLBCL patients. RNA was successfully extracted from 132 formalin-fixed paraffin-embedded (FFPE) specimens. Expression of the 6 genes comprising the model was measured and the mortality predictor score was calculated for each patient. The mortality predictor score divided patients into low-risk (below median) and high-risk (above median) subgroups with significantly different overall survival (OS; P = .002) and progression-free survival (PFS; P = .038). The model also predicted OS and PFS when the mortality predictor score was considered as a continuous variable (P = .002 and .010, respectively) and was independent of the IPI for prediction of OS (P = .008). These findings demonstrate that the prognostic value of the 6-gene model remains significant in the era of R-CHOP treatment and that the model can be applied to routine FFPE tissue from initial diagnostic biopsies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al.
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
Ann. Onc., June 30, 2009; (2009) mdp237v1.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. A. Alizadeh, A. J. Gentles, I. S. Lossos, and R. Levy
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
N. Engl. J. Med., June 25, 2009; 360(26): 2794 - 2795.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020